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TGFb functions as a tumor suppressor in some contexts and a tumor promoter in others. In a recent
issue of Cancer Cell, Bruna et al. (2007) shed light on an epigenetic mechanism that underlies this
schizophrenic behavior in malignant glioma. Their findings highlight a stem cell/cancer link.and
a potential blind spot in large-scale cancer genome sequencing projects.Transforming growth factor beta
(TGFb) is the founding member and
namesake of a large family of cyto-
kines characterized by a set of con-
served cysteine residues that fold the
proteins into rigid ‘‘cysteine knot’’ mo-
tifs through formation of intrachain
disulfide bridges. TGFb proteins acti-
vate heterodimeric cell surface recep-
tors that function as serine/threonine
protein kinases. Signaling information
is relayed from these cell surface re-
ceptors to the cell nucleus via phos-
phorylation of SMAD proteins. Phos-
phorylated SMADs relocalize from the
inner cell surface to the nucleus where
they function as transcription factors.
TGFbs play multifaceted roles in em-
bryonic development and tissue ho-
meostasis (Massague and Gomis,
2006). However they have especially
prominent functions in the area of cell
cycle control.
In cell culture, nanomolar concen-
trations of TGFb suppress the growth
of normal epithelial cells and lympho-
cytes. In transgenic mouse models,324 Developmental Cell 12, March 2007 ªmisexpression of TGFb retards the for-
mation of mammary ductal epithelium
and delays the onset of mammary
carcinomas induced by chemical and
viral carcinogens (see Bierie and
Moses [2006] and references therein).
Some human cancers acquire loss-
of-function mutations in the TGFb
signaling pathway that would ablate
these cytostatic responses (Chen
et al., 2001). These observations and
other data are consistent with the
view that TGFb and its downstream
signal generators function as classical
tumor suppressors . but there is
another side to the story.
In mice with previously established
mammary carcinomas, TGFb actually
promotes tumor invasion and metas-
tasis (Bierie and Moses [2006] and ref-
erences therein). In murine models of
skin carcinoma, TGFb functions as
a tumor suppressor at early stages of
tumor development and as a tumor
accelerant at later stages. Some hu-
man tumors retain an intact TGFb
signaling apparatus while avoiding2007 Elsevier Inc.growth arrest. In malignant gliomas,
things go even further than that.
In a recent issue of Cancer Cell,
Bruna and colleagues build upon
mounting evidence that TGFb has
proliferative/oncogenic functions in
gliomas that are channeled through
PDGFautocrine/paracrine loops (Bruna
et al. [2007] and references therein).
The point of departure for their study
is the observation that activation of
the TGFb signaling apparatus serves
as a negative prognostic indicator for
glioma patients. A direct correlation
with proliferation index and grade of
tumor and an inverse correlation with
survival provide compelling evidence
that activation of the TGFb signaling
pathway provides a selective advan-
tage to tumor cells.
How can a potent antimitotic agent
work to the advantage of malignant gli-
omas? Some of the late-stage tumor-
promoting actions of TGFb in murine
models (i.e., enhanced cell motility
and invasion, induction of angiogene-
sis, immune suppression) appear to
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Previewsreflect non-cell-autonomous interac-
tions between TGFb, tumor stroma,
and the host immune system (Bierie
and Moses, 2006). However, Bruna
et al. used immunohistochemical tech-
niques to show that the phosphory-
lated isoforms of a key TGFb signal
generator (SMAD2) are detectable in
the nucleus of the glioma cells per se.
This observation would suggest that
the promitotic function of TGFb in
gliomas is cell autonomous. To define
cell-autonomous functions of TGFb in
growth or growth arrest, the investiga-
tors identified two established glioma
cell lines that show diametrically
opposite responses to TGFb in vitro.
The U373MG glioma line displays a
mitogenic response to TGFb under
conditions where the U87MG line is
growth inhibited. Experiments with
a small-molecule inhibitor of TGFb
(LY2109761) confirmed that both the
mitogenic and the antimitogenic
responses to TGFb in these two cell
lines required activation of the TGFb
receptor kinase.
So what is the promitotic effector of
TGFb? Expression profiling was used
to compare genes that are induced by
TGFb in U373MG cells (the mitotic re-
sponse line) to genes that are induced
in U87MG cells (antimitotic response).
Comparing the transcription profiles
revealed 63 targets unique to the
U373MG line. Crunching these 63 tar-
gets through the Gene Ontology filter
revealed a subset of six genes associ-
ated with cell proliferation. Distinctive
within this set was the c-sis proto-on-
cogene encoding the BB isoform of
platelet-derived growth factor (PDGF).
The pathogenetic role of PDGF in
gliomas is well established. Essentially
100% of glioma cell lines and fresh
surgical isolates of glioma tumor tissue
express combinations of PDGF ligand
and PDGF receptor that would serve
to close an autocrine loop (Lokker
et al. [2002] and references therein).
PDGF receptors are expressed in nor-
mal astrocytes, in oligodendrocyte
progenitors, and even in adult neural
progenitor cells (Erlandsson et al.,
2006). However, in healthy brain,
PDGF ligands are generally produced
by neurons. The production of PDGF
ligands by glioma cells and cell lines
has never been well explained at amo-lecular level. Although PDGF receptor
genes are amplified in about 20% of
all gliomas, the genes encoding the
four known isoforms of PDGF (A
through D) are not usually amplified
or rearranged (Cavenee et al., 2000).
The induction of PDGF-B did not re-
quire new protein synthesis but did
require SMAD proteins being bound
to the proximal PDGFB promoter in
U373MG cells. When looking at
U87MG cells, SMADs did not bind to
the endogenous promoter. However,
TGFb was able to transactivate the
PDGFB promoter in a luciferase re-
porter assay. Together, these obser-
vations suggested that epigenetic
modifications might underlie the differ-
ential induction of PDGF-B in U373MG
and U87MG cell lines. In accord with
this view, Bruna et al. showed that
TGFb can induce PDGF-B in the
U87MG cells exposed to a DNA meth-
yltransferase inhibitor. Methylation-
specific PCR and bisulfite sequencing
confirmed that a CpG island in the 50
untranslated region of the PDGFB
(c-sis) gene was methylated in
U87MG but not in U373MG.
The U87MG and U373MG glioma
lines have been in continuous cell cul-
ture for decades and thus lack some
credibility as clinical models. However,
Bruna et al. were able to recapitulate
their results on short-term primary
cell cultures from patient-derived gli-
oma biopsies. Four out of ten cultures
from fresh clinical material showed
a mitogenic response to TGFb. These
four showed a TGFb-mediated induc-
tion of PDGFB and a nonmethylated
PDGFB gene. Three of the six lines
that did not show a mitogenic re-
sponse to TGFb had a methylated
PDGFB gene. Three other unrespon-
sive lines showed a nonmethylated
gene, indicating that mechanisms in
addition to methylation control the re-
sponse of PDGFB to TGFb.
What accounts for the differential
methylation of human glioma cells? It
is tempting to tie the data of Bruna
et al. to a mounting body of evidence
that solid tumors arise from develop-
mentally stalled tissue progenitors
(cancer stem cells). There is a general
inverse relationship between the de-
gree of methylation and the degree of
gene expression (Jaenisch and Bird,2003). During development or in repair,
cycling stem cells are relatively under-
methylated. As their progeny adopt
cell type-specific fates, exit the cycle,
and differentiate, unneeded genes
are silenced by methylation. An occa-
sional methylation ‘‘miss’’ could leave
an oncogenic land mine in place to
be tripped at some later time by a co-
activator such as TGFb.
The findings of Bruna et al. resonate
with other recent papers on the down-
regulation of putative tumor suppres-
sor genes by hypermethylation in
gliomas (Kim et al., 2006; Mueller
et al., 2007) and highlight a potential
blind spot in large-scale cancer ge-
nome sequencing projects. The na-
tional effort on sequencing of can-
cer genomes, including glioblastoma
(http://cancergenome.nih.gov), may
well identifynew targets for cancer ther-
apeutics. However, as Bruna et al. re-
mindus, theremaybeepigenetic routes
from stem cells to neoplastic disease.
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